PharVision Advisers’s Simulations Plus SLP Stock Holding History

PharVision Advisers’s Portfolio SLP Stock Details SLP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-10,313	Closed	-$155K	–	978
2025 Q3	$155K	Buy	+10,313	New	+$150K	0.09%	564

Other funds holding SLP

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Rockefeller Capital Management New York $65.2B AUM 31.44% 1-Year Est. Return

TCM

Tributary Capital Management Omaha, Nebraska $1.22B AUM 44.12% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

PharVision Advisers's SLP Position: Q4 2025 in Review

PharVision Advisers sold out of Simulations Plus (SLP) in Q4 2025, closing a stake of 10,313 shares — an estimated $155K sold.

PharVision Advisers first reported a position in SLP in Q3 2025 and held it in 1 quarter. The position peaked at $155K in Q3 2025. 169 funds tracked by Wall St. Rank hold SLP as of Q4 2025.

PharVision Advisers reported no remaining Simulations Plus position as of Q4 2025 after selling out during the quarter.
PharVision Advisers sold 10,313 Simulations Plus shares in Q4 2025, an estimated $155K.
PharVision Advisers first reported a position in Simulations Plus in Q3 2025 and held it in 1 quarter.
PharVision Advisers's Simulations Plus position peaked at $155K in Q3 2025.
169 funds tracked by Wall St. Rank held Simulations Plus as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.